Citations (126)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Jonas Westhus, Richard Noppeney, Ulrich Dührsen & Maher Hanoun. (2019) FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia. Leukemia & Lymphoma 60:4, pages 1014-1022.
Read now
Read now
Imit Kaur, Jonathan E Constance, Ken M Kosak, Michael G Spigarelli & Catherine MT Sherwin. (2015) An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 53-65.
Read now
Read now
Michael J Absalon & Franklin O Smith. (2009) Treatment strategies for pediatric acute myeloid leukemia. Expert Opinion on Pharmacotherapy 10:1, pages 57-79.
Read now
Read now
Xavier Thomas & Hervé Dombret. (2007) Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology 12:1, pages 15-28.
Read now
Read now
Marco Montillo, Francesca Ricci & Alessandra Tedeschi. (2006) Role of fludarabine in hematological malignancies. Expert Review of Anticancer Therapy 6:9, pages 1141-1161.
Read now
Read now
Marino Clavio, Ivana Pierri, Claudia Venturino, Alberto Garrone, Letizia Canepa, Maurizio Miglino, Riccardo Varaldo, Filippo Ballerini, Gian Luca Michelis, Manuela Balocco, Nabila Abdall, Simona Gatto & Marco Gobbi. (2004) Role of Liposomal Daunorubicin, Fludarabine and Cytarabine (FLAD) in the Salvage Therapy of Adult Acute Lymphoblastic Leukemia. Leukemia & Lymphoma 45:12, pages 2527-2530.
Read now
Read now
Apostolia-Maria Tsimberidou, Yesid Alvarado & Francis J Giles. (2002) Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Review of Anticancer Therapy 2:4, pages 437-448.
Read now
Read now
Brynjar Vidarsson, Rafat Abonour, Eliot C. Williams, Robert D. Woodson, Nancy J. Turman, Kyungmann Kim, Deane F. Mosher, Susan R. Wiersma & Walter L. Longo. (2001) Fludarabine and Cytarabine as a Sequential Infusion Regimen for Treatment of Adults with Recurrent, Refractory or Poor Prognosis Acute Leukemia. Leukemia & Lymphoma 41:3-4, pages 321-331.
Read now
Read now
Domenico Russo, Giancarla Pricolo, Mariagrazia Michieli, Angela Michelutti, Donatella Raspadori, Antonella Bertone, Luciana Marin, Ivana Pierri, Alessandro Bucalossi, Eliana Zuffa, Antonio De Vivo, Patrizio Mazza, Marco Gobbi, Francesco Lauria, Alfonso Zaccaria & Michele Baccarani. (2001) Fludarabine, Arabinosyl Cytosine and Idarubicin (FLAI) for Remission Induction in Poor-Risk Acute Myeloid Leukemia. Leukemia & Lymphoma 40:3-4, pages 335-343.
Read now
Read now
Marino Clavio, Simona Gatto, Germana Beltrami, Raffaella Cerri, Paola Carrara, Ivana Pierri, Letizia Canepa, Maurizio Miglino, Enrico Balleari, Bahman Masoudi, Eugenio Damasio, Riccardo Ghio, Mario Sessarego & Marco Gobbi. (2001) First Line Therapy with Fludarabine Combinations in 42 Patients with Either Post Myelodysplastic Syndrome or Therapy Related Acute Myeloid Leukaemia. Leukemia & Lymphoma 40:3-4, pages 305-313.
Read now
Read now
Angelo Michele Carella, Nicola Cascavilla, Michele Mario Greco, Lorella Melillo, Maria Rosaria Sajeva, Saverio Ladogana, Giovanni D'arena, Gianni Perla & Mario Carotenuto. (2001) Treatment of “Poor Risk” Acute Myeloid Leukemia with Fludarabine, Cytarabine and G-CSF (Flag Regimen): A Single Center Study. Leukemia & Lymphoma 40:3-4, pages 295-303.
Read now
Read now
Tadeusz Robak, Agata Wrzesień-kuś, Ewa Lech-marańda, Magorzata Kowal & Anna Dmoszyńska. (2000) Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Leukemia & Lymphoma 39:1-2, pages 121-129.
Read now
Read now
Annalisa Pellacani, Patrizia Tosi, Pier Luigizinzani, Emanuela Ottaviani, Patrizia Albertini, Massimo Magagnoli & Sante Tura. (1999) Cytotoxic Combination of Loxoribine with Fludarabine and Mafosfamide on Freshly Isolated B-Chronic Lymphocytic Leukemia Cells. Leukemia & Lymphoma 33:1-2, pages 147-153.
Read now
Read now
Giovanni Martinelli, Nicoletta Testoni, Eliana Zuffa, Giuseppe Visani, Pier Luigi Zinzani, Alfonso Zaccaria, Patrizia Farabegoli, Mario Arpinati, Marilina Amabile & Sante Tura. (1996) Flang (Fludarabine + Cytosine Arabinoside + Novantrone + G-CSF) Induces Partial Remission in Lymphoid Blast Transformation of Ph+ Chronic Myelogenous Leukaemia. Leukemia & Lymphoma 22:1-2, pages 173-176.
Read now
Read now
Maurizio Bendandi, Alfonso Zaccaria, Pier Luigi Zinzani, Giuseppe Visani, Valerio Stefanat, Fabrizio Cantagalli, Antonino Mancino, Silvia Macchi, Francesco Simoncelli & Sante Tura. (1995) Factor VIII Inhibitor Prior to and During Secondary Acute Nonlymphocytic Leukemia in a Patient with Cured Hodgkin's Disease. Leukemia & Lymphoma 16:5-6, pages 511-513.
Read now
Read now
Michael J. Keating, Susan O'brien, Lester E. Robertson, Hagop Kantarjian, Meletios Dimopoulos, Peter McLaughlin, Fernando Cabanillas, Vincent Gregoire, Li Ying-Yang, Varsha Gandhi, Elihu Estey & William Plunkett. (1994) The Expanding Role of Fludarabine in Hematologic Malignancies. Leukemia & Lymphoma 14:sup2, pages 11-16.
Read now
Read now
Varsha Gandhi, Peng Huang & William Plunkett. (1994) Fludarabine Inhibits DNA Replication: A Rationale for Its Use in the Treatment of Acute Leukemias. Leukemia & Lymphoma 14:sup2, pages 3-9.
Read now
Read now
E. Estey, S. Pierce, H. Kantarjian, S. O'brien, M. Beran, M. Andreeff, S. Escudier, C. Koller, S. Kornblau, L. Robertson & M. Keating. (1993) Treatment of Myelodysplastic Syndromes with AML-Type Chemotherapy. Leukemia & Lymphoma 11:sup2, pages 59-63.
Read now
Read now
V. Gandhi. (1993) Fludarabine for Treatment of Adult Acute Myelogenous Leukemia. Leukemia & Lymphoma 11:sup2, pages 7-13.
Read now
Read now
Articles from other publishers (107)
Martin Jädersten, Ingrid Lilienthal, Nikolaos Tsesmetzis, Magda Lourda, Sofia Bengtzén, Anna Bohlin, Cornelia Arnroth, Tom Erkers, Brinton Seashore‐Ludlow, Géraldine Giraud, Giti S. Barkhordar, Sijia Tao, Linda Fogelstrand, Leonie Saft, Päivi Östling, Raymond F. Schinazi, Baek Kim, Torsten Schaller, Gunnar Juliusson, Stefan Deneberg, Sören Lehmann, Georgios Z. Rassidakis, Martin Höglund, Jan‐Inge Henter & Nikolas Herold. (2022) Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial. Journal of Internal Medicine 292:6, pages 925-940.
Crossref
Crossref
Shenjia Huang, Yicong Bian, Chenrong Huang & Liyan Miao. (2022) Is Monitoring of the Intracellular Active Metabolite Levels of Nucleobase and Nucleoside Analogs Ready for Precision Medicine Applications?. European Journal of Drug Metabolism and Pharmacokinetics 47:6, pages 761-775.
Crossref
Crossref
Tapan M. Kadia, Farhad Ravandi, Gautam Borthakur, Marina Konopleva, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Rashmi Kanagal‐Shamanna, Xuemei Wang, Xuelin Huang, Sherry Pierce, Caitlin Rausch, Jan Burger, Alessandra Ferrajoli, Nitin Jain, Uday Popat, Zeev Estrov, Srdan Verstovsek, Elias Jabbour, Guillermo Garcia‐Manero & Hagop Kantarjian. (2021) Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology 96:8, pages 914-924.
Crossref
Crossref
Abdul Muqtadir Abbasi, Usman Shaikh, Natasha Ali & Mohammad Nadir Haider. (2021) Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience. Leukemia Research Reports 15, pages 100235.
Crossref
Crossref
Giovanni Marconi, Stefano De Polo, Giovanni Martinelli, Jacopo Nanni, Luca Bertamini, Annalisa Talami, Matteo Olivi, Simone Ragaini, Maria Chiara Abbenante, Chiara Sartor, Emanuela Ottaviani, Maria Teresa Bochicchio, Sarah Parisi, Maria Chiara Fontana, Gianluca Cristiano, Maddalena Raffini, Carmen Baldazzi, Nicoletta Testoni, Francesca Bonifazi, Stefania Paolini, Antonio Curti, Michele Cavo & Cristina Papayannidis. (2020) Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. Leukemia Research, pages 106497.
Crossref
Crossref
Giovanni Marconi, Annalisa Talami, Maria Chiara Abbenante, Chiara Sartor, Sarah Parisi, Jacopo Nanni, Luca Bertamini, Simone Ragaini, Matteo Olivi, Stefano de Polo, Gianluca Cristiano, Maria Chiara Fontana, Maria Teresa Bochicchio, Emanuela Ottaviani, Mario Arpinati, Mariarosaria Sessa, Carmen Baldazzi, Lucia Caso, Nicoletta Testoni, Michele Baccarani, Francesca Bonifazi, Giovanni Martinelli, Stefania Paolini, Michele Cavo, Cristina Papayannidis & Antonio Curti. (2020) MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. European Journal of Haematology 105:1, pages 47-55.
Crossref
Crossref
Jonathan Canaani, Meital Nagar, Gabriel Heering, Chen Gefen, Ronit Yerushalmi, Noga Shem-Tov, Yulia Volchek, Drorit Merkel, Abraham Avigdor, Avichai Shimoni, Ninette Amariglio, Gidi Rechavi & Arnon Nagler. (2020) Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. Oncotarget 11:23, pages 2233-2245.
Crossref
Crossref
Longzhen Cui, Yan Liu, Yifan Pang, Tingting Qian, Liang Quan, Zhiheng Cheng, Yifeng Dai, Xu Ye, Ying Pang, Jinlong Shi, Xiaoyan Ke, Depei Wu & Lin Fu. (2019) Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Therapy 27:1-2, pages 1-14.
Crossref
Crossref
Jonas Westhus, Richard Noppeney, Christine Schmitz, Michael Flasshove, Ulrich Dührsen & Maher Hanoun. (2020) Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. Acta Haematologica 143:5, pages 438-445.
Crossref
Crossref
Matthew Ettleson, Kale S Bongers, Kaitlyn Vitale, Anthony J. Perissinotti, Tycel Phillips & Bernard L. Marini. (2018) Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. Journal of Oncology Pharmacy Practice 25:3, pages 731-734.
Crossref
Crossref
Nahoko Hatsumi, Shuichi Miyawaki, Takahiro Yamauchi, Akihiro Takeshita, Norio Komatsu, Noriko Usui, Yukihiro Arai, Fumihiro Ishida, Takeshi Morii, Yasuhiko Kano, Michinori Ogura, Shinichiro Machida, Kazuhiro Nishii, Sumihisa Honda, Kazunori Ohnishi & Tomoki Naoe. (2019) Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. International Journal of Hematology 109:4, pages 418-425.
Crossref
Crossref
Irina Garmaevna Budaeva, L.L. Girshova, E.G. Ovsyannikova, E.N. Goryunova, O.V. Kulemina, D.V. Zaitsev, D.V. Motorin, R.Sh. Badaev, D.B. Zammoeva, V.V. Ivanov, K.V. Bogdanov, O.S. Pisotskaya, Yu.V. Mirolyubova, T.S. Nikulina, Yu.A. Alekseeva & A.Yu. Zaritskey. (2019) Prediction of FLAG ± Ida Regimen Efficacy in Patients with Relapsed/ Refractory Acute Myeloid Leukemia. Clinical oncohematology 12:3, pages 289-296.
Crossref
Crossref
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Miguel Ángel Sanz & Pau Montesinos. (2018) Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Annals of Hematology 97:7, pages 1115-1153.
Crossref
Crossref
Z.A. Nurgat, H. Alzahrani, M. Lawrence, A. Mannan, M. Ashour, W. Rasheed & M. Aljurf. (2017) Intracranial hypertension secondary to high dose cytosine arabinoside ? A case study. Journal of Infection and Chemotherapy 23:5, pages 319-322.
Crossref
Crossref
Fabio Guolo, Paola Minetto, Marino Clavio, Maurizio Miglino, Roberto Massimo Lemoli & Marco Gobbi. (2017) Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives. BioScience Trends 11:1, pages 110-114.
Crossref
Crossref
Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva-Maria Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Dietmar Geissler, Wolfgang R. Sperr, Sabine Hojas, Inga M. Rogulj, Johannes Andel & Richard Greil. (2016) Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal & Michael Boyiadzis. (2016) Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 24:2, pages 73-80.
Crossref
Crossref
Jeffrey C. Bryan & Elias J. Jabbour. (2015) Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. Drugs & Aging 32:8, pages 623-637.
Crossref
Crossref
Claudio Annaloro, Antonella Costa, Nicola S Fracchiolla, Gabriella Mometto, Silvia Artuso, Giorgia Saporiti, Elena Tagliaferri, Federica Grifoni, Francesco Onida & Agostino Cortelezzi. (2015) Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report. Clinical Case Reports 3:7, pages 650-655.
Crossref
Crossref
Xiaojin Cai, Jialing Wei, Yi He, Dongling Yang, Erlie Jiang, Yong Huang, Mingzhe Han & Sizhou Feng. (2014) A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. International Journal of Clinical Pharmacy 37:1, pages 44-52.
Crossref
Crossref
Jorge E. Cortes, Stuart L. Goldberg, Eric J. Feldman, David A. Rizzeri, Donna E. Hogge, Melissa Larson, Arnaud Pigneux, Christian Recher, Gary Schiller, Krzysztof Warzocha, Hagop Kantarjian, Arthur C. Louie & Jonathan E. Kolitz. (2015) Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 121:2, pages 234-242.
Crossref
Crossref
Alaa Fadhil Alwan, Bassam Francis Matti, Alaadin Sahham Naji & Ali Muhammad Jawad. (2013) The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients. Indian Journal of Hematology and Blood Transfusion 30:4, pages 231-235.
Crossref
Crossref
Pawel Robak & Tadeusz Robak. (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treatment Reviews 39:8, pages 851-861.
Crossref
Crossref
Maria Ilaria Del Principe, Francesco Buccisano, Luca Maurillo, Daniela Venditti, Mariagiovanna Cefalo, Chiara Sarlo, Luigi Di Caprio, Ambra Di Veroli, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Fabio Di Piazza, Giulio Colandrea, Fabio Conti, Giovanni Del Poeta, Sergio Amadori & Adriano Venditti. (2013) Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. Thrombosis Research 132:5, pages 511-514.
Crossref
Crossref
Marino Clavio, Fabio Cruciani, Paola Minetto, Fabio Guolo, Filippo Ballerini, Carlo Marani, Enrico De Astis, Sara Aquino, Micaela Bergamaschi, Laura Mitscheunig, Raffaella Grasso, Nicoletta Colombo, Chiara Ghiggi, Davide Lovera, Giordana Pastori, Daniele Avenoso, Maurizio Miglino & Marco Gobbi. (2013) De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”. Annals of Hematology 92:10, pages 1309-1318.
Crossref
Crossref
Brian McLaughlin, Annie Im, Anastasios Raptis, Mounzer Agha, Jing-Zhou Hou, Robert Redner, Shrina Duggal, Yan Lin, Clay Smith & Michael Boyiadzis. (2012) Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. International Journal of Hematology 96:6, pages 743-747.
Crossref
Crossref
Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi, William Plunkett, Varsha Gandhi, Stefan Faderl, Susan O'Brien, Gautam Borthakur, Tapan Kadia, Jan Burger, Marina Konopleva, Mark Brandt, Xuelin Huang & Hagop Kantarjian. (2012) Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 12:4, pages 244-251.
Crossref
Crossref
Shuichi Miyawaki. (2012) Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. International Journal of Hematology 96:2, pages 171-177.
Crossref
Crossref
L. Domínguez Senín, J.N. Rodríguez Rodríguez, M.T. Garrido Martínez, M. Sánchez Argáiz & E. Martín Chacón. (2012) Efectividad y seguridad del régimen FLAG-IDA en leucemias agudas resistentes o recidivantes. Farmacia Hospitalaria 36:4, pages 261-267.
Crossref
Crossref
Steven W. Paugh, Mary V. Relling & William E. Evans. 2013. Childhood Leukemias. Childhood Leukemias
309
331
.
Paola Quarello, Massimo Berger, Elisa Rivetti, Chiara Galletto, Riccardo Masetti, Rosaria Manicone, Elena Barisone, Andrea Pession & Franca Fagioli. (2012) FLAG-liposomal Doxorubicin (Myocet) Regimen for Refractory or Relapsed Acute Leukemia Pediatric Patients. Journal of Pediatric Hematology/Oncology 34:3, pages 208-216.
Crossref
Crossref
Dhaval R. Mehta, Kenneth A. Foon, Robert L. Redner, Anastasios Raptis, Mounzer Agha, Jing-Zhou Hou, Shrina Duggal, The Minh Luong, James J. Schlesselman & Michael Boyiadzis. (2011) Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. Leukemia Research 35:7, pages 885-888.
Crossref
Crossref
Shuiying Hu, Hongmei Niu, Hiroto Inaba, Shelley Orwick, Charles Rose, John C. Panetta, Shengping Yang, Stanley Pounds, Yiping Fan, Christopher Calabrese, Jerold E. Rehg, Dario Campana, Jeffrey E. Rubnitz & Sharyn D. Baker. (2011) Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. JNCI: Journal of the National Cancer Institute 103:11, pages 893-905.
Crossref
Crossref
James K. Mangan & Selina M. Luger. (2011) Salvage therapy for relapsed or refractory acute myeloid leukemia. Therapeutic Advances in Hematology 2:2, pages 73-82.
Crossref
Crossref
Lia Gore & Margaret Macy. 2011. Principles of Anticancer Drug Development. Principles of Anticancer Drug Development
589
601
.
Alexander E. Perl, Margaret T. Kasner, Donald E. Tsai, Dan T. Vogl, Alison W. Loren, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, Noelle V. Frey, Sunita D. Nasta, Elizabeth O. Hexner, Jamil K. Dierov, Cezary R. Swider, Adam Bagg, Alan M. Gewirtz, Martin Carroll & Selina M. Luger. (2009) A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia. Clinical Cancer Research 15:21, pages 6732-6739.
Crossref
Crossref
Mike G. Martin, Kristan M. Augustin, Geoffrey L. Uy, John S. Welch, Lindsay Hladnik, Sagun Goyal, Divya Tiwari, Ryan S. Monahan, Richard M. Reichley, Amanda F. Cashen, Keith Stockerl‐Goldstein, Peter Westervelt, Camille N. Abboud, John F. DiPersio & Ravi Vij. (2009) Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G‐CSF. American Journal of Hematology 84:11, pages 733-737.
Crossref
Crossref
Marco Montillo, Francesca Ricci, Alessandra Tedeschi, Anna Maria Cafro, Anna Maria Nosari, Michele Nichelatti, Laura Marbello & Enrica Morra. (2009) Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. Leukemia Research 33:8, pages 1072-1078.
Crossref
Crossref
Pei Lin, Lei Chen, Rajyalakshmi Luthra, Sergej N Konoplev, Xuemei Wang & L Jeffrey Medeiros. (2008) Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Modern Pathology 21:8, pages 1029-1036.
Crossref
Crossref
Masaya Okada, Yoshihiro Fujimori, Mahito Misawa, Shunro Kai, Toshiyuki Nakajima, Yoshiko Okikawa, Atsushi Satake, Hisayuki Itoi, Hiroyuki Takatsuka, Takeyoshi Itsukuma, Keisuke Nishioka, Hiroya Tamaki, Kazuhiro Ikegame, Hiroshi Hara & Hiroyasu Ogawa. (2008) Unrelated Umbilical Cord Blood Transplantation Using a TBI/FLAG Conditioning Regimen for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation 14:8, pages 896-903.
Crossref
Crossref
Jerzy Hołowiecki, Sebastian Grosicki, Sławomira Kyrcz-Krzemien, Aleksander B. Skotnicki, Beata Piatkowska-Jakubas, Krzysztof Warzocha, Ilona Seferynska & Barbara Zdziarska. (2007) Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot study. Annals of Hematology 87:5, pages 361-367.
Crossref
Crossref
Agnieszka Wierzbowska, Tadeusz Robak, Agnieszka Pluta, Ewa Wawrzyniak, Barbara Cebula, Jerzy Hołowiecki, Sławomira Kyrcz-Krzemień, Sebastian Grosicki, Sebastian Giebel, Aleksander B. Skotnicki, Beata Piątkowska-Jakubas, Kazimierz Kuliczkowski, Marek Kiełbiński, Krystyna Zawilska, Janusz Kłoczko & Agata Wrzesień-Kuś. (2007) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem. European Journal of Haematology 80:2, pages 115-126.
Crossref
Crossref
Syed Abutalib & Martin S. Tallman. 2008. Acute Leukemias. Acute Leukemias
57
76
.
Marino Clavio, Luana Vignolo, Alessandra Albarello, Riccardo Varaldo, Ivana Pierri, Gioacchino Catania, Manuela Balocco, Gianluca Michelis, Maurizio Miglino, Annunziata Manna, Enrico Balleari, A. Michele Carella, Mario Sessarego, Maria Teresa Van Lint, Andrea Bacigalupo & Marco Gobbi. (2007) Adding low‐dose gemtuzumab ozogamicin to fludarabine, Ara‐C and idarubicin (MY‐FLAI) may improve disease‐free and overall survival in elderly patients with non‐M3 acute myeloid leukaemia: results of a prospective, pilot, multi‐centre trial and comparison with a historical cohort of patients. British Journal of Haematology 138:2, pages 186-195.
Crossref
Crossref
Isabelle Hubeek, Gert-Jan L. Kaspers, Gert J. Ossenkoppele & Godefridus J. Peters. 2007. Deoxynucleoside Analogs In Cancer Therapy. Deoxynucleoside Analogs In Cancer Therapy
119
152
.
Shinji Kishi, William E. Evans & Mary V. Relling. 2010. Childhood Leukemias. Childhood Leukemias
391
413
.
J. Holowiecki, S. Grosicki, M. Sadus-Wojciechowska, L. Kachel, A. Hellmann, A. Mital, A.B. Skotnicki, B. Piatkowska-Jakubas, W.W. Jedrzejczak, M. Paluszewska, M. Wach, B. Marianska, A. Wrzesien-Kus, M. Krawczyk-Kulis & J. Wojnar. (2005) Addition of Cladribine to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia Patients. Transplantation Proceedings 37:10, pages 4482-4487.
Crossref
Crossref
Domenico Russo, Michele Malagola, Antonio Vivo, Mauro Fiacchini, Giovanni Martinelli, Pier P. Piccaluga, Daniela Damiani, Anna Candoni, Angela Michielutti, Maurizio Castelli, Nicoletta Testoni, Emanuela Ottaviani, Michela Rondoni, Giancarla Pricolo, Patrizio Mazza, Eliana Zuffa, Alfonso Zaccaria, Donatella Raspadori, Monica Bocchia, Francesco Lauria, Alessandro Bonini, Paolo Avanzini, Luigi Gugliotta, Giuseppe Visani, Renato Fanin & Michele Baccarani. (2005) Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology 131:2, pages 172-179.
Crossref
Crossref
A. Wrzesień-Kuś, T. Robak, A. Wierzbowska, E. Lech-Marańda, A. Pluta, E. Wawrzyniak, A. Krawczyńska, K. Kuliczkowski, G. Mazur, M. Kiebiński, A. Dmoszyńska, M. Wach, A. Hellmann, W. Baran, J. Hołowiecki, S. Kyrcz-Krzemień & S. Grosicki. (2005) A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Annals of Hematology 84:9, pages 557-564.
Crossref
Crossref
Stefan FaderlVarsha GandhiSusan O'BrienPeter BonateJorge CortesElihu EsteyMiloslav BeranWilliam WierdaGuillermo Garcia-ManeroAlessandra FerrajoliZeev EstrovFrancis J. GilesMin DuMonica KwariMichael KeatingWilliam PlunkettHagop Kantarjian. (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:3, pages 940-947.
Crossref
Crossref
Marino Clavio, Claudia Venturino, Ivana Pierri, Alberto Garrone, Maurizio Miglino, Letizia Canepa, Enrico Balleari, Manuela Balocco, Gian Luca Michelis, Filippo Ballerini & Marco Gobbi. (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Annals of Hematology 83:11, pages 696-703.
Crossref
Crossref
J Holowiecki, S Grosicki, T Robak, S Kyrcz-Krzemien, S Giebel, A Hellmann, A Skotnicki, W W Jedrzejczak, L Konopka, K Kuliczkowski, B Zdziarska, A Dmoszynska, B Marianska, A Pluta, K Zawilska, M Komarnicki, J Kloczko, K Sulek, O Haus, B Stella-Holowiecka, W Baran, B Jakubas, M Paluszewska, A Wierzbowska, M Kielbinski & K Jagoda. (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18:5, pages 989-997.
Crossref
Crossref
Francis J Giles, Jorge E Cortes, Hagop M Kantarjian, Susan M O’Brien, Elihu Estey & Miloslav Beran. (2004) A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leukemia Research 28:4, pages 353-357.
Crossref
Crossref
Nicole Lamanna & Mark Weiss. 2004. Treatment of Leukemia and Lymphoma. Treatment of Leukemia and Lymphoma
107
125
.
Wolfgang Hiddemann, Heinz Huber & Claus R. BartramW. Kern, T. Haferlach & W. Hiddemann. 2004. Die Onkologie. Die Onkologie
1847
1915
.
Gunnar Juliusson, Martin Höglund, Karin Karlsson, Christina Löfgren, Lars Möllgård, Christer Paul, Ulf Tidefelt & Magnus Björkholm. (2003) Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. British Journal of Haematology 123:5, pages 810-818.
Crossref
Crossref
Apostolia Tsimberidou, Jorge Cortes, Deborah Thomas, Guillermo Garcia-Manero, Srdan Verstovsek, Stephan Faderl, Maher Albitar, Hagop Kantarjian, Elihu Estey & Francis J. Giles. (2003) Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research 27:10, pages 893-897.
Crossref
Crossref
A. Wrzesień-Kuś, T. Robak, E. Lech-Marańda, A. Wierzbowska, A. Dmoszyńska, M. Kowal, J. Hołowiecki, S. Kyrcz-Krzemień, S. Grosicki, S. Maj, A. Hellmann, A. Skotnicki, W. Je˛drzejczak & K. Kuliczkowski. (2003) A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). European Journal of Haematology 71:3, pages 155-162.
Crossref
Crossref
Imad A. Tabbara & Richard M. Ingram. (2003) Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation. Experimental Hematology 31:7, pages 559-566.
Crossref
Crossref
M B Thomas, C Koller, Y Yang, Y Shen, S O'Brien, H Kantarjian, J Davis & E Estey. (2003) Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia 17:5, pages 990-993.
Crossref
Crossref
D. Pastore, G. Specchia, P. Carluccio, A. Liso, A. Mestice, R. Rizzi, G. Greco, C. Buquicchio & V. Liso. (2003) FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Annals of Hematology 82:4, pages 231-235.
Crossref
Crossref
Apostolia Tsimberidou, Elihu Estey, Jorge Cortes, Deborah Thomas, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia‐Manero, Michael Keating, Maher Albitar, Susan O'Brien, Hagop Kantarjian & Francis Giles. (2003) Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes. Cancer 97:6, pages 1481-1487.
Crossref
Crossref
E. Estey, F. Giles, J. Cortes, M. Beran, C. Koller, S. O’Brien, S. Pierce & H. Kantarjian. 2003. Acute Leukemias IX. Acute Leukemias IX
394
403
.
W. Kern, A. Kerkhoff, A. Matylis, A. Grüneisen, C. Huber, B. Wörmann, T. Büchner, J. Ohnesorge, W. D. Ludwig & W. Hiddemann. 2003. Acute Leukemias IX. Acute Leukemias IX
385
393
.
Zheng Shi, D. Sampath & W. Plunkett. 2003. Acute Leukemias IX. Acute Leukemias IX
97
108
.
Igor Espinoza-Delgado & Dan L. Longo. 2003. Allogeneic Stem Cell Transplantation. Allogeneic Stem Cell Transplantation
83
99
.
A. Anagnostopoulos & S. Giralt. (2002) Critical review on non-myeloablative stem cell transplantation (NST). Critical Reviews in Oncology/Hematology 44:2, pages 175-190.
Crossref
Crossref
Javier de la Rubia, Ana I. Regadera, Guillermo Mart??n, Jos? Cervera, Guillermo F. Sanz, Jes?s A. Mart??nez, Isidro Jarque, Inmaculada Garc??a, Rafael Andreu, Federico Moscard?Carmen Jim?nez, Susana Moll?Luis Benlloch & Miguel A. Sanz. (2002) FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leukemia Research 26:8, pages 725-730.
Crossref
Crossref
Lance H. Leopold, Mark S. Berger & Jay Feingoldr. (2002) Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia. Clinical Lymphoma 2, pages S29-S34.
Crossref
Crossref
Sergio Giralt, Athanasios Anagnostopoulos, Munir Shahjahan & Richard Champlin. (2002) Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Seminars in Hematology 39:1, pages 57-62.
Crossref
Crossref
S. Giralt. (2002) Update on non-myeloablative stem cell transplantation for hematologic malignancies. International Journal of Hematology 76:S1, pages 176-183.
Crossref
Crossref
Issa Khouri, Sergio Giralt & Richard Champlin. 2002. Non-Myeloablative Allogeneic Transplantation. Non-Myeloablative Allogeneic Transplantation
137
147
.
Elihu H. EsteyPeter F. ThallJorge E. CortesFrancis J. GilesSusan O'BrienSherry A. PierceXuemei WangHagop M. KantarjianMiloslav Beran. (2001) Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98:13, pages 3575-3583.
Crossref
Crossref
R. J. Frewin & S. A. Johnson. (2001) The role of purine analogue combinations in the management of acute leukemias. Hematological Oncology 19:4, pages 151-157.
Crossref
Crossref
M. Macheta & J. A. Liu Yin. (2001) Recent advances in the treatment of AML. Hematological Oncology 19:3, pages 107-118.
Crossref
Crossref
G. Jackson, P. Taylor, G. M. Smith, R. Marcus, A. Smith, P. Chu, T. J. Littlewood, A. Duncombe, M. Hutchinson, A. B. Mehta, S. A. Johnson, P. Carey, M. J. Mackie, P. S. Ganly, G. E. Turner, M. Deane, S. Schey, J. Brookes, S. M. Tollerfield & M. P. Wilson. (2001)
A multicentre, open, non‐comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony‐stimulating factor in relapsed and refractory acute myeloid leukaemia and
de novo
refractory anaemia with excess of blasts in transformation
. British Journal of Haematology 112:1, pages 127-137.
Crossref
Crossref
M Ahlmann, C Lanvers, K Lümkemann, C Rössig, A Freund, M Baumann & J Boos. (2001) Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells. Leukemia 15:1, pages 69-73.
Crossref
Crossref
W. Kern, A. Matylis, T. Grüneisen, C. Huber, A. Grote-Metke, B. Wörmann, T. Büchner, J. Ohnesorge, W. D. Ludwig & W. Hiddemann. 2001. Acute Leukemias VIII. Acute Leukemias VIII
578
587
.
W. Kern, A. Matylis, T. Grüneisen, C. Huber, A. Grote-Metke, B. Wörmann, T. Büchner, J. Ohnesorge, W. D. Ludwig & W. Hiddemann. 2001. Acute Leukemias VIII. Acute Leukemias VIII
201
209
.
N Blot, P Schneider, P Young, C Janvresse, D Dehesdin, P Tron & JP Vannier. (2000) Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplantation 26:8, pages 903-905.
Crossref
Crossref
Avichai Shimoni, Sergio Giralt, Issa Khouri & Richard Champlin. (2000) Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: Non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. Current Oncology Reports 2:2, pages 132-139.
Crossref
Crossref
JL Byrne, C Stainer, G Cull, AP Haynes, EM Bessell, G Hale, H Waldmann & NH Russell. (2000) The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplantation 25:4, pages 411-417.
Crossref
Crossref
Jorge Cortes & Hagop M. Kantarjian. (2000) Promising Approaches in Acute Leukemia. Investigational New Drugs 18:1, pages 57-82.
Crossref
Crossref
Sergio A. Giralt. 2000. Cell Therapy. Cell Therapy
185
193
.
Charles A. Koller, Hagop M. Kantarjian, Eric J. Feldman, Susan O'Brien, Mary Beth Rios, Elihu Estey & Michael Keating. (1999) A Phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer 86:11, pages 2246-2251.
Crossref
Crossref
A. H. STRICKLAND, C. SEYMOUR, H. M. PRINCE, M. WOLF, S. JUNEJA & E. H. JANUSZEWICZ. (2008) Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia. Australian and New Zealand Journal of Medicine 29:4, pages 556-558.
Crossref
Crossref
A.J. McCarthy, L.A. Pitcher, I.M. Hann & A. Oakhill. (1999) FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Medical and Pediatric Oncology 32:6, pages 411-415.
Crossref
Crossref
Sergio Giralt, Issa Khouri & Richard Champlin. 1999. Advances in Allogeneic Hematopoietic Stem Cell Transplantation. Advances in Allogeneic Hematopoietic Stem Cell Transplantation
97
108
.
Fleischhack, Hasan, Graf, Mann & Bode. (2001) IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. British Journal of Haematology 102:3, pages 647-655.
Crossref
Crossref
Marco Montillo, Salvatore Mirto, Maria Concetta Petti, Roberto Latagliata, Silvana Magrin, Antonio Pinto, Vittorina Zagonel, Giuseppina Mele, Alessandra Tedeschi & Felicetto Ferrara. (1998) Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. American Journal of Hematology 58:2, pages 105-109.
Crossref
Crossref
V. Gandhi, E. E. Estey, F. Seymour, D. Sampath, M. Du, M. Ayers, M. Keating & W. Plunkett. 1998. Acute Leukemias VII. Acute Leukemias VII
577
583
.
W. Kern, C. Aul, G. Maschmeyer, R. Schönrock-Nabulsi, W. D. Ludwig, A. Bartholomäus, P. Bettelheim, B. Wörmann, Th. Büchner & W. Hiddemann. 1998. Acute Leukemias VII. Acute Leukemias VII
943
953
.
Sergio GiraltElihu EsteyMaher AlbitarKoen van BesienGabriela RondónPaolo AnderliniSusan O'BrienIssa KhouriJames GajewskiRakesh MehraDavid ClaxtonBorje AnderssonMiloslav BeranDonna PrzepiorkaCharles KollerSteve KornblauMartin KörblingMichael KeatingHagop KantarjianRichard Champlin. (1997) Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. Blood 89:12, pages 4531-4536.
Crossref
Crossref
Steven Grant. 1997.
197
233
.
M. J. Keating. 1997. Acute Leukemias VI. Acute Leukemias VI
380
387
.
Wolfgang Kern, Eberhard Schleyer, Michael Unterhalt, Bernhard W�rmann, Thomas B�chner & Wolfgang Hiddemann. (1997) High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Cancer 79:1, pages 59-68.
Crossref
Crossref
Harry Openshaw, Neal E. Slatkin, Anthony S. Stein, David R. Hinton & Stephen J. Forman. (1996) Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 78:9, pages 1899-1905.
Crossref
Crossref
Giuseppe Visani, Patrizia Tosi, Pier Luigi Zinzani, Silvia Manfroi, Emanuela Ottaviani, Annarita Cenacchi, Paola Carrara, Marino Clavio, Marco Gobbi & Sante Tura. (2009)
FLAG (Fludarabine, Cytarabine, G‐CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression:
in vitro
and
in vivo
effects
. European Journal of Haematology 56:5, pages 308-312.
Crossref
Crossref
Jeffrey W. Taub & Yaddanapudi Ravindranath. (1996) 7 Treatment of childhood acute myeloid leukaemia. Bailli?re's Clinical Haematology 9:1, pages 129-146.
Crossref
Crossref
Michael J. Keating. 1996. Acute Leukemias V. Acute Leukemias V
572
577
.
Varsha Gandhi, Min Du, Amy J. Chapman, Peng Huang, Elihu Estey, Michael J. Keating & William Plunkett. 1996. Acute Leukemias V. Acute Leukemias V
25
31
.
John C. Byrd, Jeffrey B. Hargis, Kent E. Kester, Duane R. Hospenthal, Sarah W. Knutson & Louis F. Diehl. (1995) Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for pneumocystis carinii pneumonia prophylaxis. American Journal of Hematology 49:2, pages 135-142.
Crossref
Crossref
F. LEONI, S. CIOIXI, G. GIULIANI, A. PASCARELLA, R. CAPORALE, F. SALTI, L. CERVI & P. Rossi FERRINI. (2008) Attenuated‐dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. British Journal of Haematology 90:1, pages 169-174.
Crossref
Crossref
M.J. Keating, P. McLaughlin, W. Plunkett, L.E. Robertson, S. O'Brien, V. Gandhi, V. Gregoire, L. Yang & F. Cabanillas. (1994) Original article: Fludarabine – present status and future developments in chronic lymphocytic leukemia and lymphoma. Annals of Oncology 5, pages S79-S83.
Crossref
Crossref
William Plunkett. 1994. Innovative Antimetabolites in Solid Tumours. Innovative Antimetabolites in Solid Tumours
11
19
.
Samer Suki, Hagop Kantarjian, Varsha Gandhi, Elihu Estey, Susan O'Brien, Miloslav Beran, Mary Beth Rios, William Plunkett & Michael Keating. (1993) Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 72:7, pages 2155-2160.
Crossref
Crossref
Christina D. Drenberg, Anang Shelat, Shelley J. Orwick, Mengyu Li, Jae Yoon Jeon, Marissa Pioso, Daelynn R. Buelow, Shuiying Hu, Hiroto Inaba, Raul C. Ribeiro, Jeffrey E. Rubnitz, Tanja A. Gruber, R. Kiplin Guy & Sharyn D. Baker. (2018) Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal.
Crossref
Crossref